Literature DB >> 18184971

Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis.

D Mark Davies, Simon R Johnson, Anne E Tattersfield, J Chris Kingswood, Jane A Cox, Deborah L McCartney, Tim Doyle, Frances Elmslie, Anand Saggar, Petrus J de Vries, Julian R Sampson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18184971     DOI： 10.1056/NEJMc072500

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  75 in total

1.  Pulmonary lymphangioleiomyomatosis associated with retroperitoneal lymphangioleiomyomas.

Authors:  Anastasia Oikonomou; Argyris Tzouvelekis; Petros Zezos; Demostehenes Bouros; Panos Prassopoulos
Journal:  BMJ Case Rep       Date:  2012-01-18

2.  A National Heart, Lung, and Blood Institute history and perspective on lymphangioleiomyomatosis.

Authors:  Hannah Peavy; Dorothy Gail; James Kiley; Susan Shurin
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

3.  Volumes to learn: advancing therapeutics with innovative computed tomography image data analysis.

Authors:  Michael L Maitland
Journal:  Clin Cancer Res       Date:  2010-07-19       Impact factor: 12.531

Review 4.  Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex.

Authors:  Petrus J de Vries
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

5.  mTORC2 is required for proliferation and survival of TSC2-null cells.

Authors:  Elena A Goncharova; Dmitry A Goncharov; Hua Li; Wittaya Pimtong; Stephen Lu; Irene Khavin; Vera P Krymskaya
Journal:  Mol Cell Biol       Date:  2011-04-11       Impact factor: 4.272

6.  Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma.

Authors:  Darcy A Krueger; Marguerite M Care; Karen Agricola; Cindy Tudor; Maxwell Mays; David Neal Franz
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

Review 7.  Common corruption of the mTOR signaling network in human tumors.

Authors:  S Menon; B D Manning
Journal:  Oncogene       Date:  2008-12       Impact factor: 9.867

Review 8.  Tuberous sclerosis complex: a brave new world?

Authors:  Kevin C Ess
Journal:  Curr Opin Neurol       Date:  2010-04       Impact factor: 5.710

9.  Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.

Authors:  Francis X McCormack; Nishant Gupta; Geraldine R Finlay; Lisa R Young; Angelo M Taveira-DaSilva; Connie G Glasgow; Wendy K Steagall; Simon R Johnson; Steven A Sahn; Jay H Ryu; Charlie Strange; Kuniaki Seyama; Eugene J Sullivan; Robert M Kotloff; Gregory P Downey; Jeffrey T Chapman; MeiLan K Han; Jeanine M D'Armiento; Yoshikazu Inoue; Elizabeth P Henske; John J Bissler; Thomas V Colby; Brent W Kinder; Kathryn A Wikenheiser-Brokamp; Kevin K Brown; Jean F Cordier; Cristopher Meyer; Vincent Cottin; Jan L Brozek; Karen Smith; Kevin C Wilson; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2016-09-15       Impact factor: 21.405

10.  Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.

Authors:  Nancy Lee; Chelsey L Woodrum; Alison M Nobil; Aubrey E Rauktys; Michael P Messina; Sandra L Dabora
Journal:  BMC Pharmacol       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.